

Delhi-based Bioheaven360 Genotec secures Rs 1 Cr funding to accelerate growth

16 January 2023 | News

The startup plans to add more products in the microbiology and molecular biology domain



Bioheaven360 Genotec, a biotechnology startup based in New Delhi, has secured Rs1 crore in funding from Digital Futurists Angel Network DFAN, a global community-backed angel network. Bioheaven360 will use this funding to expand its facility and infrastructure for the production of medical devices, as well as continue the development of its innovative state-of-the-art products.

Bioheaven360's long-term vision is to discover new cost-effective molecules for treating dreadful diseases and using Albased data insights to enhance medical practices, predict risks early, and help people live longer healthier lives. Bioheaven360 desires to become one of the biggest biotech companies in the world. In 2023, it plans to add more products in the microbiology and molecular biology domain and expand its reach across India and release for testing the immuno-molecules.

Shailendra Vyas, PhD, Director of Bioheaven, said, "We are thrilled to receive this funding from DFAN, which will allow us to accelerate our growth and bring our innovative medical technologies to market and enable us to take significant steps towards achieving our long-term vision and short-term goals. We believe that our innovative approach to biotechnology will make a real difference in the lives of people suffering from critical diseases."

The company's in-house research team is focused on identifying novel molecular markers for predictive risk assessment and pharmacogenomics-based drug targeting. It also works on CRISPR-based diagnostics, therapeutics, and vaccines for cancer, cardiovascular diseases, and infectious diseases.